Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer
Mené sur 52 patients atteints d'un carcinome épidermoïde de l'oesophage de stade avancé (âge : 18-75 ans ; durée médiane de suivi : 7,5 mois), cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du camrélizumab combiné à l'apatinib en traitement de deuxième ligne
With clear evidence of activity for immune checkpoint inhibitors across the spectrumof solid tumour malignancies, identifying combination therapies to augment their efficacyis a high research priority. In gastro-oesophageal cancer, immune checkpoint inhibitorsinitially received approval for chemotherapy-refractory gastric cancer, then approval for second-line therapy in oesophageal squamous cancer, and more recently approval in combination with first-line chemotherapy in oesophagogastriccancer. Although a benefit might depend on expression of PD-L1, in the USA the first-lineapproval in oesophagogastric cancer was given regardless of PD-L1 status.
The Lancet Gastroenterology & Hepatology , commentaire, 2021